País: Països Baixos
Idioma: neerlandès
Font: CBG-MEB (College ter Beoordeling van Geneesmiddelen)
NATRIUMIBANDRONAAT 1-WATER SAMENSTELLING overeenkomend met ; IBANDRONINEZUUR
Stada Arzneimittel AG
M05BA06
NATRIUMIBANDRONAAT 1-WATER COMPOSITION corresponding to ; IBANDRONINEZUUR
Concentraat voor oplossing voor infusie
AZIJNZUUR (E 260), GECONCENTREERD ; NATRIUMACETAAT 3-WATER (E 262) ; NATRIUMCHLORIDE ; NATRIUMHYDROXIDE (E 524) ; WATER VOOR INJECTIE,
Intraveneus gebruik
Ibandronic Acid
Hulpstoffen: AZIJNZUUR (E 260), GECONCENTREERD; NATRIUMACETAAT 3-WATER (E 262); NATRIUMCHLORIDE; NATRIUMHYDROXIDE (E 524); WATER VOOR INJECTIE;
2012-09-03
NL PL Ibandronic acid 2+6 mg CSI, NL2128 PACKAGE LEAFLET: INFORMATION FOR THE PATIENT IBANDRONINEZUUR STADA 2 MG/2 ML, CONCENTRAAT VOOR OPLOSSING VOOR INFUSIE IBANDRONINEZUUR STADA 6 MG/6 ML, CONCENTRAAT VOOR OPLOSSING VOOR INFUSIE Ibandronic acid READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. Keep this leaflet. You may need to read it again. If you have any further questions, ask your doctor or pharmacist. If you get any of the side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Ibandroninezuur STADA 2 mg and 6 mg is and what it is used for 2. What you need to know before you receive Ibandroninezuur STADA 2 mg and 6 mg 3. How to receive Ibandroninezuur STADA 2 mg and 6 mg 4. Possible side effects 5. How to store Ibandroninezuur STADA 2 mg and 6 mg 6. Contents of the pack and other information 1. WHAT IBANDRONINEZUUR STADA 2 MG AND 6 MG IS AND WHAT IT IS USED FOR Ibandroninezuur STADA 2 mg and 6 mg concentrate for solution for infusion contains the active substance ibandronic acid. This belongs to a group of medicines called bisphosphonates. Ibandronic acid is used in adults and prescribed to you if you have breast cancer that has spread to your bones (called bone “metastases”) It helps to prevent your bones from breaking (fractures). It helps to prevent other bone problems that may need surgery or radiotherapy. Ibandronic acid can also be prescribed if you have a raised calcium level in your blood due to a tumour. Ibandronic acid works by reducing the amount of calcium that is lost from your bones. This helps to stop your bones from getting weaker. 2. WHAT YOU NEED TO KNOW BEFORE YOU RECEIVE IBANDRONINEZUUR STADA 2 MG AND 6 MG DO NOT RECEIVE IBANDRONINEZUUR STADA 2 MG AND 6 MG if you are allergic to ibandronic acid or any of the other ingredients of this medicine (listed in section 6). if you hav Llegiu el document complet
NL SmPC Ibandronic acid NL2128 (2+6 mg) SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Ibandroninezuur STADA 2 mg/2 ml, concentraat voor oplossing voor infusie Ibandroninezuur STADA 6 mg/6 ml, concentraat voor oplossing voor infusie 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One vial with 2 ml concentrate for solution for infusion contains 2 mg ibandronic acid (as 2.25 mg ibandronic acid, monosodium salt, monohydrate). One vial with 6 ml concentrate for solution for infusion contains 6 mg ibandronic acid, (as 6.75 mg ibandronic acid monosodium salt, monohydrate) One ml concentrate for solution for infusion contains 1 mg ibandronic acid (as 1.13 mg ibandronic acid, monosodium salt, monohydrate). Excipient(s) with known effect Sodium (less than 1 mmol per dose) For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Concentrate for solution for infusion. Clear, colourless solution. pH of the undiluted product: 4.9-5.5 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Ibandronic acid is indicated in adults for Prevention of skeletal events (pathological fractures, bone complications requiring radiotherapy or surgery) in patients with breast cancer and bone metastases. Treatment of tumour-induced hypercalcaemia with or without metastases. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Patients treated with ibandronic acid concentrate for solution for infusion should be given the package leaflet and the patient reminder card. Ibandronic acid therapy should only be initiated by physicians experienced in the treatment of cancer. Posology _Prevention of skeletal events in patients with breast cancer and bone metastases_ The recommended dose for prevention of skeletal events in patients with breast cancer and bone metastases is 6 mg intravenous injection given every 3-4 weeks. The dose should be infused over at least 15 minutes. A shorter (i.e. 15 min) infusion time should only be used for patients with normal renal function or mild renal impairment. There are no data available Llegiu el document complet